A Citigroup analyst initiated coverage on Acadia with a Buy rating and announced a price target of $38. Additionally the US District Court for the District of Delaware has issued a summary judgment in favor of Acadia, affirming the validity of the NUPLAZID (pimavanserin) '740 composition of matter patent on all grounds
- Forums
- ASX - By Stock
- NEU
- Acadia
Acadia, page-678
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.88 |
Change
-0.020(0.10%) |
Mkt cap ! $2.552B |
Open | High | Low | Value | Volume |
$20.22 | $20.44 | $19.85 | $2.961M | 147.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4015 | $21.34 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.90 | 71 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 272 | 19.910 |
7 | 369 | 19.900 |
4 | 284 | 19.890 |
4 | 502 | 19.880 |
4 | 499 | 19.870 |
Price($) | Vol. | No. |
---|---|---|
19.940 | 177 | 6 |
19.950 | 267 | 3 |
19.960 | 246 | 3 |
19.970 | 252 | 4 |
19.980 | 504 | 4 |
Last trade - 15.59pm 04/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |